



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/650,592	08/27/2003	Noubar B. Afeyan	COTH-P01-001	7920

56155 7590 02/08/2011

ROPES & GRAY LLP
IPRM - Floor 43
Prudential Tower
800 Boylston Street
Boston, MA 02199-3600

EXAMINER

MEAH, MOHAMMAD Y

ART UNIT	PAPER NUMBER
----------	--------------

1652

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

02/08/2011

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatentMail@ropesgray.com
USPatentMail2@ropesgray.com

Office Action Summary	Application No.	Applicant(s)	
	10/650,592	AFEYAN ET AL.	
	Examiner	Art Unit	
	MD. YOUNUS MEAH	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 13 September 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) See Continuation Sheet is/are pending in the application.
- 4a) Of the above claim(s) 135, 137, 147, 150, 162 and 163 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) See Continuation Sheet is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>11/11/10</u> | 6) <input type="checkbox"/> Other: _____ |

Continuation of Disposition of Claims: Claims pending in the application are 5,7-9,26,29,31,37,48-51,56,58,70,72,76,78,108,110,117,127-129,131-135,137,147,150,156,158,159 and 161-167.

Continuation of Disposition of Claims: Claims rejected are 5,7-9,26 ,29,31,37,48-51,56, 58,70,72,76,78,108, 110117,127-129,131-134,156,158,159 and 161, 164-167.

DETAILED ACTION

Claims 5, 7-9, 26, 29, 31, 37, 48-51, 56, 58, 70, 72, 76, 78, 108, 110, 117, 127-129, 131-135, 137, 147, 150 and 156, 158-159, 161-167 are pending. In response to a previous non-final action mailed on 05/12/2010, Applicants on 09/13/2010 amended claims , 5, 29, 164, 166-167, cancelled claims 27, 69, 74, 157, 160 and added new claims 168-169. Since a zymogen could be an inactive protease, claim 56 will be included in the elected group and will be examined. Since claim 110 comprise elected subject matter, claim 110 will be examined with the elected group. Claims 135, 137, 147, 150 and 162-163 are withdrawn.

Continued Examination under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set

forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants' response of 4/2/010 is acknowledged. Applicants' arguments filed on 03/05/010 have been fully considered but they are found unpersuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Applicants' arguments filed on 09/13/2010 have been fully considered but they are found unpersuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Claim Rejection- 35 U.S.C 112 Written Description

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 1, 5,7-9,26 ,29,31,37,48-51,56, 58,70,72,76,78,108, 110117,127-129,131-134,156,158,159 and 161, 164-167 (depend on claim 1) , 168 and 169 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a **NEW MATTER** rejection.

Amended claim 1 and new claims 168-169 introduce new matter in reciting “the polypeptide is not fibrin” and “with the proviso that the protease domain is not urokinase plasminogen activator”. Introduction of “the polypeptide is not fibrin” and “with the proviso that the protease domain is not urokinase plasminogen activator” in the claims is a new matter because neither the specification nor the claims as originally filed disclose these exclusions as preferred embodiments of the claimed invention. The Examiner has not been able to find support in the specification for the recited exclusions, i.e., “ the polypeptide is not fibrin” and “with the proviso that the protease domain is not urokinase plasminogen activator. Thus, there is no indication that the current claims were within the scope of the invention as conceived by Applicants at the

Art Unit: 1652

time the application was filed. Accordingly, Applicants are required to cancel the new matter in response to this Office Action.

Applicants' argument is considered but found unpersuasive because the specification does not have support for the recited exclusions.

35 U.S.C 102 Rejections

Rejection of claims 5, 7-9, 37, 48-51, 58, 70, 72, 74, 76, 78, 108, 127-129, 156, 157-158, 164-165 under 35 U.S.C. 102(b) as being anticipated by Holvoet *et al.* (JBC 1991, vol.266, pp 19717-19724) is withdrawn after amendment of claim 5.

CLAIM Rejection - 35 U.S.C 103a

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims [5, 7-9, 37, 70, 72, 76, 78, 108, 117, 127-129, 156, , 164-165 are rejected under 35 U.S.C. 103(a) by Davis et al. (WO 00/64485) in view of Bhatia et al (Intl. J. Cancer 2000, 85, 571-57, IDS).

Davis et al. teach fusion proteins wherein enzymes (serine protease, chymotrypsin, matrix metalloprotease, etc) which catalyze degradation of a specific

Art Unit: 1652

target are conjugated to binding partner such as, protein or peptide or an antibody (immunoglobulin, Fab, F(ab)₂ claim 27), wherein said fusion protein has greater (catalytic or more than one,) activity than the unconjugated molecule. The chimeric protein of Davis et al. bind to the target polypeptide and antagonize/inhibit /degrade a wide variety of receptors and/or intermediary signaling molecules such as cytokines, EGF-like factors, etc. Davis et al. use the fusion protein as a pharmaceutical composition wherein the targeted enzyme is protease and use the pharmaceutical composition for autoimmune disease, infectious diseases , cancer, etc. Davis et al. chimeric protein is chemically cross-linked fusion protein not a cotranslation fusion protein encoded by a recombinant nucleic acid made by of respective genes. Protein conjugates can be made either by chemical conjugation or by gene fusion methods (applicants specification page 2 lines 26-30), but gene fusion methods have some particular advantages (see last paragraph of column one of page 571 of Bhatia et al Intl. J. Cancer 2000, 85, 571-577). It is well known in the prior art how to make fusion proteins by translation of a chimeric gene fusion (such as references supplied in the amendment of 5/7/08 by the applicants and also Bhatia et al Intl. J. Cancer 2000, 85, 571-577). Bhatia et al teach antibody-targeted enzymes made by the gene fusion method. Therefore, one knowledgeable in prior art is **motivated** to make the protein conjugate of Davis et al by gene fusion methodology as taught by Bhatia et al.

As such it would have been obvious to one of ordinary skill in the art to make the fusion protein of Davis et al. by the method Bhatia et al. and use the resulting adzyme to inactivate substrate polypeptides by catalyzing the proteolytic cleavage of the said

Art Unit: 1652

substrate polypeptide. Claims 70, 72, 76, 78, 165 is included in rejection because of the reasons explained below: Claim 165 requires the substrate polypeptide from specific target such as, protein aggregate cleaved by a protease or a specific protease such as a metalloprotease, which is taught by Davis et al. The fusion protein of Davis et al cleave peptide bonds of any substrate polypeptide in a blood stain or milk stain (paragraph 0067) which can be regarded as protein aggregate. With regard to claims, 70, 72, 76, 78, Davis et al teach that the substrate can be receptors, signaling molecules like cytokines, EGF-like factors, etc., which are compounds found in a biological fluid of an animal, including blood.

Claim 48 is rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al. (WO 00/64485) in view of Bhatia et al (Intl. J. Cancer 2000, 85, 571-57, IDS) as described above, and further in view of Tamburini et al (US PAT 5,981,208)).

Davis et al., and Bhatia et al are described above. However neither Davis et al., nor Bhatia et al et al. teach the said substrate is from amyloid deposit.

Tamburini et al teach the use of secretase (a metalloprotease, column 2) which catalyse the proteolytic cleavage of amyloid protein precursor in amyloid deposit (column 2) for the detection of Alzheimer's diseases. Detection of Amyloid deposit or amyloid protein precursor is important to diagnose Alzheimer's disease (Tamburini et al column 1)

As such it would have been obvious to one of ordinary skill in the art to make a fusion protein comprising secretase conjugated to an antibody molecule that binds to

Art Unit: 1652

the amyloid protein precursor in an amyloid deposit by the method as taught by Davis et al., and Bhatia et al and use the resulting adzyme to detect likelihood of Alzheimer's diseases by cleaving amyloid protein.

Claim 58 is rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al. (WO 00/64485) in view of, Bhatia et al (Intl. J. Cancer 2000, 85, 571-57, IDS) as described above, and further in view of Dolinar et al. (*Food technol and biotech.* 2000, 38, 5-9)..

Davis et al., and Bhatia et al are described above. However neither Davis et al., nor Bhatia et al et al. teach purification of a fusion protein comprising a protease domain using a reversible protease inhibitor.

Use of protease inhibitor in protein purification is well known in prior art. Dolinar et al. teach MMTS (methyl methane-thiosulfonate), a reversible protease inhibitor in the purification and refolding of a cystine proteinase type protein (page 6, column 2 last parg.). Therefore, one of skill in the art would have been **motivated to** purify **a** fusion protein complex comprising a protease using a protease inhibitor so that said fusion protein complex would not be cleaved by the protease.

As such it would have been obvious to one of ordinary skill in the art to use a protease inhibitor to purify the protease-containing fusion protein complex of Davis et al described above. One of ordinary skill in the art has a reasonable expectation of success at obtaining an adzyme which is resistant to autocatalytic proteolysis in view of the teachings of Dolinar et al. Therefore, the invention as a whole would have been

Art Unit: 1652

prima facie obvious to a person of ordinary skill in the art at the time the invention was made.

Claims 49-50, 158 are rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al. (WO 00/64485) in view of Bhatia et al and further in view Steinhauer et al (Virology 1999, 258, pp 1-20).

Davis et al., and Bhatia et al. are described above

Steinhauer et al teach that activated hemagglutinin is essential for infectivity because it allows virus particles to attach to cell receptors and it also mediates fusion of the viral and cellular membranes (page 2, right column, first full paragraph) Inactivation of virus such as the influenza virus is of major medicinal importance (see Steinhauer et al.; introduction). One of skill in the art would clearly understand that proteolytic degradation of the **activated** hemagglutinin so that it no longer can be used to attach viral particles to cell receptors or mediate fusion of viral and cellular membranes would reduce infection because of the role of the activated protein in viral infectivity.

As such it would have been obvious to one of ordinary skill in the art to make a fusion protein comprising protease conjugated to influenza virus specific antibody molecule by the method as taught by Davis et al., and Bhatia et al and use the resulting adzyme to inactivate influenza virus type substrate polypeptides by catalyzing the proteolytic cleavage of the said substrate polypeptides.

Art Unit: 1652

Claims 56, 110, and 167 are rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al. (WO 00/64485) in view of Bhatia et al and further in view Schooltink et al (J. Interferon and Cytokine Res 2002, 5, 505-516).

Davis et al., and Bhatia et al. are described above

However, neither Davis et al., nor Bhatia et al. teach a fusion protein that inhibit binding of TNF-alpha to TNF-alpha receptor.

Schooltink et al (J. Interferon and Cytokine Res 2002, 5, 505-516) teach TNFR (page 508) and also teach the importance of TNF-alpha receptors in inflammatory diseases. and drug development.. One of skill in the art know that pro-inflammatory molecule TNF-alpha play a key role in inflammatory diseases (Page 508, Schooltink et al). Degrading TNF-alpha by protease will decrease inflammatory response. It is well known in the art that TNF-alpha bind to cell surface receptors such as p55 (Schooltink et al page 508). Therefore one of skilled in art is motivated to use a fusion protein which comprise a protease domain and a targeting domain that bind on p55 TNF alpha receptor so that protease domain could cleave the TNF-alpha molecule in order to treat inflammatory diseases.

As such it would have been obvious to one of ordinary skill in the art to make the fusion protein of Davis et al. by the method Bhatia et al. and use the resulting adzyme to inactivate substrate polypeptides in TNF-alpha by catalyzing the proteolytic cleavage of the said substrate polypeptide to decrease inflammation.

Art Unit: 1652

Claims 26, 29, 31, 159, 161 and 165-166 are rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al. (WO 00/64485) in view of Bhatia et al (Intl. J. Cancer 2000, 85, 571-57) further in view of Guo et al. (Biotech. and Bioeng. 2000, 70, 456-463).

The teachings of Davis et al., and Bhatia et al described above. However Davis et al. nor Bhatia et al teach the use of a linker in between the catalytic domain and the binding domain.

Guo et al. teach fusion proteins wherein an enzyme (ASNase) is conjugated to an immunoglobulin or fragment thereof or antibody (scFV) by a linker polypeptide (Gly₄Ser)₃. Guo et al also teach the advantage of (Gly₄Ser)₃ as a linker, such as enhanced hydrophilicity and conformational flexibility (page 457, column 1 2nd paragraph). Therefore, one of ordinary skill in the art is motivated to make a fusion protein (as taught by Davis et al.) wherein an enzyme (serine protease which catalyze the degradation of a specific target) is conjugated to an antibody (immunoglobulin which binds to the target) by (Gly₄Ser)₃ type linker.

As such it would have been obvious to one of ordinary skill in the art to make a fusion protein as taught by Davis et al by fusing serine protease which catalyze the degradation of a specific target to an antibody *via* a linker as taught by Guo *et al.* and use the resulting fusion protein to inactivate polypeptide substrates by catalyzing the proteolytic cleavage of the said polypeptide substrates.

Art Unit: 1652

Claim 51 is rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al., and Bhatia et al in view of Debburman *et al.* (PNAS 1997 94, 13938-13943). This rejection is maintained as discussed at length in the previous office action and discussed it again.

The teachings of Davis et al., and Bhatia et al are described above. Davis et al., and Bhatia et al do not teach use of their fusion protein to degrade target comprising prion protein molecule.

Debburman et al. teach prion proteins comprise protease labile PrPc and protease resistant, PrPSc. Debburman et al. also teach that a protease labile prion protein converts to protease resistant, PrPSc. Protease resistant form of prion (PrPSc, page 13938 column 1, 2nd paragraph) is involved in diseases. Therefore, one of ordinary skill in the art is motivated to make fusion proteins as taught by Davis et al., and Bhatia et al. comprising enzymes (protease) conjugated to binding partners wherein the binding partner is an antibody specific to a prion molecule and use it to catalyze the degradation of the prion molecule before it turn into the resistant form.

As such it would have been obvious to one of ordinary skill in the art to make a fusion protein comprising protease conjugated to prion specific antibody molecule by the method as taught by Davis et al., and Bhatia et al and use the resulting adzyme to inactivate prion type substrate polypeptides by catalyzing the proteolytic cleavage of the said substrate prion polypeptides.

Art Unit: 1652

Claims 131-134 are rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al., and Bhatia et al in view of Sanderson et al. (Medic. Res Rev 1999)..

The teachings of Davis et al., and Bhatia et al are described above.

However, Davis et al., and Bhatia et al do not teach said a pharmaceutical preparation comprising a reversible inhibitor safe to humans.

Sanderson *et al.* (Medic. Res Rev 1999, 19, 179-197) teach a small molecule non-covalent binding protease inhibitor that used with a pharmaceutical composition which is reversible and safe in humans (abstract).

Use of protease inhibitors in a protein sample is well known in the prior art because proteases auto catalyze their own degradation (Sanderson et al). In order to extend the life of pharmaceutical preparation comprising the fusion protein and to preserve its effectiveness in humans, one of ordinary skill in the art is motivated to add a reversible protease inhibitor which is safe to humans (as taught by Sanderson et al). As such it would have been obvious to one of ordinary skill in the art to make pharmaceutical preparation comprising a fusion protein as taught by Davis et al., and Bhatia et al and combine it with a reversible protease inhibitor as taught by Sanderson et al. so that said inhibitor is safe for humans and the pharmaceutical preparation is effective.

Argument

Applicants' arguments files on 09/13/2010 have been fully considered and are deemed moot in view of the withdrawal of the rejections over the teachings of Holvoet et al.

Double Patenting Rejection

The provisional rejection of claims 5, 7-9, 26-27, 29, 31, 35, 37, 52-53, 58, 69-70, 72, 74, 76, 78, 108, 119 and 127-29, 131-134 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 4-5, 19-27, 30-34, 37-41 of copending Application No.10/792498 and 10/650,591 is maintained.

Examiner agrees with applicant that the provisional double patenting rejections may be withdrawn when all claims are otherwise allowable if the copending application is not allowable. All the examined claims of the instant application are rejectable on other grounds. Since applicant did not submit terminal disclaimer, the rejections are maintained.

Allowable Subject Matter/Conclusion

None of the claims are allowable.

concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah
Examiner, Art Unit 1652

/Delia M. Ramirez/
Primary Examiner, Art Unit 1652

Application/Control Number: 10/650,592
Art Unit: 1652

Page 14